Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 12/20 | 0.62 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.35 |
| ▸ | CPN1 | P15169 | 1/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24322793 | 0.89 | F2 (0.62) | F2DPP4DPP8TPSAB1 | |
| SCHEMBL24322770 | 0.80 | F2 (0.56) | F2DPP4DPP8TPSAB1CPN1 | |
| SCHEMBL7391125 | 0.80 | F2 (0.56) | F2DPP4DPP8TPSAB1CPN1 | |
| SCHEMBL24322551 | 0.80 | F2 (0.59) | F2DPP4DPP8TPSAB1CPN1 | |
| Hydrochloric Acid SCHEMBL9003170 | 0.79 | F2 (0.56) | F2TPSAB1CPN1CPB2 | |
| Acetic Acid SCHEMBL8918912 | 0.77 | F2 (0.97) | F2 | |
| SCHEMBL24322799 | 0.77 | F2 (0.58) | F2TPSAB1CPN1CPB2 | |
| SCHEMBL24324301 | 0.74 | F2 (0.43) | F2TPSAB1CPN1CPB2 | |
| SCHEMBL24323889 | 0.73 | F2 (0.61) | F2TPSAB1 | |
| SCHEMBL7390858 | 0.72 | F2 (0.43) | F2TPSAB1CPN1CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | F2 3514/4885DPP4 532/4885DPP8 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.